Background: Anecdotal evidence suggests that male sex hormones are proatherogenic. We hypothesized that the male sex hormone receptor, the androgen receptor (AR), acts as a molecular switch in sex-specific inflammatory signaling in vascular cells. Materials and methods: AR expression in human umbilical vein endothelial cells (HUVECs), human monocyte-derived macrophages (MDMs) or HeLa cells was modulated by transfection with AR siRNA or human AR cDNA expression vector. Activity and expression levels were measured by luciferase reporter assays, Western blotting or real-time PCR analysis. Results: AR knockdown reduced expression of vascular cell adhesion molecule-1 (VCAM-1) in genetically male HUVECs. Conversely, AR upregulation in genetically female HUVECs induced VCAM-1 expression and increased dihydrotestosterone-stimulated monocyte adhesion. Co-transfection of an AR expression vector with VCAM-1 or NF-kB-reporter vectors into phenotypically female, AR-negative HeLa cells confirmed AR regulation of VCAM-1 expression as well as AR activation of NF-kB. AR upregulation was not sufficient to increase ICAM-1 levels in female HUVECs or lipoprotein metabolism gene expression in female MDMs, despite AR knockdown limiting expression in their male counterparts. Conclusions: AR acts as a molecular switch to induce VCAM-1 expression. Low AR levels in female HUVECs limit NF-kB/VCAM-1 induction and monocyte adhesion and could contribute to the gender bias in cardiovascular disease. Unidentified factors in female cells limit induction of other proatherogenic genes not primarily regulated by NF-kB.
Introduction
In all developed countries, men have an earlier and greater incidence of cardiovascular disease than that found in agematched women (1) . Studies have clearly defined a protective role for female hormones in this dichotomy (2) , however, the role of male hormones, or androgens, remains ambiguous. Anecdotal evidence suggests that androgens are proatherogenic (3) , yet this has not been upheld in animal studies examining effects on early lesion development (4) (5) (6) . It has been shown in vitro that androgens can modulate two key processes in early lesion formation that could contribute to the male predisposition to atherosclerosis. The potent nonaromatizable androgen, dihydrotestosterone (DHT), has been shown to increase monocyte-endothelial cell adhesion via upregulation of vascular cell adhesion molecule-1 (VCAM-1) (7, 8) . DHT also stimulates intracellular cholesterol ester accumulation in monocyte-derived macrophages (MDMs) and increases the rate of cholesterol ester hydrolysis (9) , critical processes leading to foam cell formation (10) .
An important facet of these findings was the ability of DHT to stimulate these effects in a sex-specific manner. Published data from this laboratory has shown that DHT (4-400 nmol/L) dose-dependently induces VCAM-1 expression in male, but not female, endothelial cells (ECs) (7, 11) . Similarly, DHT (4-400 nmol/L) enhances cholesteryl ester uptake in MDMs from male, but not female, donors (8) in conjunction with sex-specific induction of genes involved in lysosomal degradation (lysosomal acid lipase or LAL) and post-lysosomal processing wacyl coA: cholesterol acyltransferase 1 (ACAT1) and hormone-sensitive lipase (HSL)x (9) . Sex-specific effects in both MDMs and ECs correlates with higher expression of the cognate receptor for androgen action, the androgen receptor (AR), in male-derived cells compared to female-derived cells (7, 12) and the higher AR expression in male ECs was associated with higher basal levels of VCAM-1 expression (7). Both DHT-induced VCAM-1 expression in male ECs (7, 8) and cholesterol ester accumulation in male MDMs (12) could be blocked by the AR antagonist, hydroxyflutamide (HF), consistent with an AR-dependent mechanism. Differential AR expression between the sexes could therefore underlie the gender-specific effects of DHT on both monocyte adhesion and foam cell formation.
We postulate the AR is the molecular switch in males driving the sex-specific effects of DHT on VCAM-1 expression, monocyte adhesion and cholesterol ester accumulation, and that low levels of cellular AR in females confers protection from these proatherogenic androgen effects. The aims of this study were therefore to investigate the ability of AR overexpression in genetically female ECs and MDMs to promote these responses.
Materials and methods

Plasmids
The AR expression vector, pSVARo, was provided by Professor Albert O. Brinkmann (Department of Endocrinology and Reproduction, Erasmus University Rotterdam, The Netherlands) (13) . An AR short interfering RNA (AR siRNA) expression plasmid was purchased from Millipore (Millipore, Billerica, MA, USA). pZEOSV2 q was purchased from Invitrogen (Invitrogen Corporation, Carlsbad, CA, USA). pNF-kB-luciferase and pRL-TK (used as a control for transfection efficiency) were purchased from Promega (Promega Corporation, Madison, WI, USA). VCAM-1 promoter (F2)-luciferase reporter vector was constructed as previously described (7).
Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated from male or female infant umbilical cords by the collagenase dispersion method as described previously (14) and maintained in phenol-red free M199 supplemented with 20% charcoal-stripped human serum, 0.5% EC growth promoter, 100 U/mL penicillin and 100 mg/mL streptomycin. EC monolayers were propagated on gelatincoated flasks (8) , passaged by trypsinization at 90% confluency and used at passages 2-4. HeLa cells (ATCC, Manassas, VA, USA) were maintained in RPMI 1640 medium supplemented with 10% charcoal-stripped fetal bovine serum and seeded at 1=10 5 cells/cm 2 in 12-well plates for transfection experiments. Human monocytes were isolated from white cell concentrates (buffy coats) from the peripheral blood of healthy human volunteers (Red Cross Blood Bank) as described previously (15) . The monocytes were used immediately for the monocyte-adhesion assays or plated onto 12-well plates at 1=10 5 cells/cm 2 and cultured in phenol red-free RPMI 1640 medium supplemented with 20% charcoal-stripped human serum for a 10-day period to allow monocyte-macrophage differentiation. Treatments consisted of medium containing 0.1% ethanol as control (used to dissolve DHT); (ii) DHT 400 nmol/L; (iii) DHT 400 nmol/LqHF 4 mmol/L and HF 4 mmol/L. Cells were treated with DHT at 400 nmol/L only, as we have previously published that this dose elicits maximal effects on both cell adhesion and macrophage lipid accumulation and yet reflects those seen at the more physiological doses of 4 and 40 nmol/L (7, 8, 12) .
Transient cell transfections and luciferase measurements
One day before transfection, HeLa cells were seeded at 1=10 5 cells per well in a 12-well plate. Cells were transfected with Gene-PORTER 2 (Genlantis, San Diego, CA, USA, 5 mL), serum-free M199 (20 mL) and plasmid mix diluted in DNA diluent (25 mL).
The plasmid mixes used were: (i) pNF-kB-luciferase 100 ngq pZEOSV2 q 100 ng (a control plasmid to make up total plasmid DNA to 200 ng)qpRL-TK 40 ng; (ii) pNF-kB-luciferase 100 ngq pSVARo 100 ngqpRL-TK 40 ng; (iii) pVCAM-1(F2)-luciferase 100 ngqpZEOSV2 q 100 ngqpRL-TK 40 ng; (iv) pVCAM-1(F2)-luciferase 100 ngqpSVARo 100 ngqpRL-TK 40 ng. The plasmidGenePORTER 2 suspensions were incubated with cells for 4-6 h, were then washed with phosphate buffered saline (PBS) before 1 mL fresh medium was added and cells were incubated for a further 48 h. Cells were lysed with passive lysis buffer (250 mL/well; Promega) and analyzed for luciferase and renilla activity using the Dual-Luciferase Reporter System (Promega).
HUVECs were seeded (1=10 5 cells/well) in a 12-well plate. To silence AR expression in HUVECs from male donors, a mixture of 8 mg of AR siRNA plasmid, serum-free M199 (20 mL) and GenePORTER2 (5 mL) was prepared and transfection performed (Genlantis). After 16 h incubation, cells were washed twice with PBS, 1 mL fresh medium was added and the cells were incubated for a further 24 h. Total RNA was then harvested from the cells for real-time PCR analysis. To increase AR expression in HUVECs from female donors, 3=10 6 Overexpression of AR in genetically female human monocytederived macrophages (HMDMs) was performed by transfection of the HMDMs on days 7-8 with pSVARo (0.3 mg) and 5 mg/mL DEAE-Dextran for 30 min at 378C. Medium (1.5 mL) was then added to the cells and cells were incubated for a further 1.5 h after which time the growth medium was changed and the cells were incubated for a further 24 h. The transfected cells were subsequently treated with either vehicle control (0.1% ethanol) or DHT (400 nmol/L) for 24 h before harvesting total RNA for real-time PCR analysis.
Real-time PCR
Total RNA was extracted from cells using TRI reagent (SigmaAldrich, Castle Hill, NSW, Australia) and the concentration normalized to 100 ng/mL using the SYBR Green II assay (Molecular Probes, Invitrogen, Melbourne, Australia). Specific cDNA was reverse transcribed from 100 ng of total RNA using iSCRIPT (BioRad, Regents Park, NSW, Australia), according to the manufacturer's protocol. An aliquot of each cDNA sample (1.2 mL) was amplified by real-time PCR in reaction mixtures containing primers (12 pmol each) and iQ SYBR Green Supermix. Amplification was performed in an iCycler iQ thermocycler (Bio-Rad) with thermal cycle conditions: 958C for 3 min, followed by 35 cycles at the annealing temperature of specific primer sets (T m ) for 30s and 728C for 30s (Table 1) . Relative changes in mRNA gene expression between treatments were determined by the ''Delta-delta'' comparative (DDC T ) method (16) and normalized using the reference genes, 18S and b2-microglobulin. Primer sequences are listed in Table 1 .
Western blot analysis
Whole protein lysate was extracted from HUVECs. Briefly, cells were harvested with trypsin and washed with cold PBS after centrifugation. Cells were lysed by the addition of RNA lysis buffer and then incubated on ice for 20 min. Cell lysate was cleared by centrifugation and the supernatant collected for protein estimation. SDS-PAGE in 8% polyacrylamide resolving gels was used to separate total protein according to size (Bio-Rad electrophoresis unit). Resolved protein samples were transferred to PVDF membranes in transfer buffer at 30 V overnight in the cold room or 70 V for 3 h at room temperature. Membranes were then blocked with 5% skim ATG TAG TGT CAT GGG CTG TG  60  VCAM1-R  GGA ATG AGT AGA GCT CCA CC  ICAM1-F  CCA TCT ACA GCT TTC CGG CGC  60  ICAM1-R  CTC TGG GGT GGC CTT CAG CA  AR-F  CAA AAG AGC CGC TGA AGG GAA ACA  55  AR-R  TTC TTC AGC TTC CGG GCT CCC AGA  ACAT1-F  AGT TGA CAG CAG AGG CAG AG  55  ACAT1-R  GGA TAA AGA GAA TGA GGA milk powder in Tris buffered saline Tween-20 (TBST) for 1 h, washed with TBST (3=) before overnight incubation with human monoclonal AR antibody (1:500 dilution, AR441/sc7305, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were then washed in TBST (3=) and incubated with secondary antibody conjugated to horseradish peroxidase for 2 h at room temperature. The membrane was then washed three times with TBST, and immunodetection was accomplished with enhanced chemiluminescence (Amersham Biosciences, Castle Hill, NSW, Australia). Membranes were directly digitized and band densities measured using Quantity One Software (Bio-Rad).
Cell adhesion assay
HUVECs from female donors (transfected with the AR expression plasmid as described above) were seeded in gelatin-coated 12-well plates at 1=10 5 cells/mL for 24 h before exposure to the following treatments: (1) 0.1% ethanol and (2) DHT 400 nmol/L. After the treatment period, monocyte-endothelial cell adhesion assays were performed as described previously (8) .
Statistical analysis
Results are reported as mean"SEM. Statistical significance between groups was assessed using the unpaired two-sided Student's t-test. Multiple comparisons were performed using one-way analysis of variance (ANOVA) and Bonferroni's post-hoc analysis where appropriate. A p-value -0.05 was considered statistically significant.
Results
AR upregulation in female cells increases VCAM-1 but not ICAM-1 expression
Genetically female ECs express relatively little AR protein compared to male ECs (Figure 1 ). To determine whether the absence of DHT-mediated induction of VCAM-1 expression observed previously in female-derived ECs (7) is a consequence of low AR expression, female-derived HUVECs were transfected with an AR expression vector (pAR). AR expression noticeably increased in transfected versus nontransfected cells. Elevated AR levels led to a 2.3-fold increase in VCAM-1 expression (p-0.05 compared to nontransfected controls) but had no significant effect on ICAM-1 expression (Figure 2A) . We next determined, whether the AR-induced increase in VCAM-1 expression in femalederived cells was associated with an increase in monocyte binding. One of the earliest pathogenic events in the development of atherosclerosis is the binding of monocytes to the endothelium, orchestrated by increased expression of VCAM-1 on the cell surface of endothelial cells. Monocyteendothelial cell adhesion assays were performed on female HUVECs transiently transfected with the AR expression vector (pSVARo) then exposed to vehicle or DHT (400 nmol/L). In female HUVECs, overexpression of AR alone did not significantly increase monoctye adhesion, however, in the presence of DHT-liganded AR, monocyte adhesion increased dramatically (20%, p-0.05 vs. non-treated transfected controls) ( Figure 2B ). DHT failed to increase monocyte adhesion in non-transfected female HUVECs, therefore highlighting that AR-induced VCAM-1 expression leads to a physiologically significant atherogenic endpoint.
AR silencing in male ECs reduces both VCAM-1 and ICAM-1 expression
To test that the converse is also true, that lowering AR expression decreases VCAM-1 expression, male-derived HUVECs were transfected with siRNA targeting AR mRNA. It was demonstrated that a 2.4-fold reduction in AR mRNA levels (p-0.005 compared to non-transfected controls) led to a 7.7-fold reduction in VCAM-1 expression (p-0.005 compared to non-transfected controls) and a 1.5-fold reduction in ICAM-1 expression (p-0.05 compared to non-transfected controls) (Figure 3 ), unequivocally demonstrating a role for the AR in VCAM-1 and ICAM-1 expression in malederived ECs.
AR upregulation in phenotypically female cells increases NF-kB activity
To investigate the findings in female cells further, HeLa cells which are phenotypically female and do not express AR were transiently transfected with an AR expression vector (pSVARo) and a VCAM-1 promoter luciferase reporter construct. AR expression in HeLa cells increased VCAM-1 promoter activity 1.7-fold (p-0.05 compared to nonpSVARo transfected controls) (Figure 4) showing that increased AR was activating VCAM-1 gene transcription.
As we previously identified that DHT-stimulated AR activates NF-kB and that it is activated NF-kB that drives the DHT-induced VCAM-1 expression in male cells (7), we next investigated whether increased AR in phenotypically female cells also led to NF-kB activation. HeLa cells were transfected with the AR expression vector (pSVARo) and an NFkB-luciferase reporter vector. AR expression increased NF-kB-luciferase activity 1.8-fold (p-0.05 vs. non-pSVARo transfected controls) (Figure 4) confirming that AR when present in high enough amounts can modulate NF-kB activity in female ECs.
AR upregulation in female MDMs does not induce lipoprotein metabolism genes
The accumulation of cholesteryl esters in macrophages leads to foam cell formation, a second important event in early atherosclerotic plaque formation. We have previously shown that DHT increases lipid accumulation in human monocytederived macrophages (MDMs) in a sex-specific manner, with the effect measured in male but not female cells and associated with DHT-induced expression of the lipoprotein metabolism genes ACAT1, LAL, HSL and caveolin-2 (CAV-2) (9). Given the AR dependence of VCAM-1 in human endothelial cells, we tested whether the expression of the HMDMs were transfected with pAR to increase AR levels. Then, 24 h after transfection, cells were treated with DHT (pAR-DHT; 400 nmol/L) or vehicle control (pAR-C; 0.1% ethanol) for 24 h. Total protein was extracted and Western blot analysis was used to measure AR levels relative to b-actin levels. Membranes were directly digitized and Quantity One was used to measure band densities. All AR levels were normalized to b-actin levels. Data are presented as mean"SEM. *p-0.05 vs. corresponding control (oneway ANOVA with Bonferroni's post-hoc analysis).
lipid metabolism genes were similarly modulated by increasing AR levels in MDMs. Female MDMs were transfected with pAR and were treated or not treated with DHT (400 nmol/L, Figure 5 ). In female MDMs overexpressing AR there was no significant increase in ACAT, LAL or CAV-2 mRNA levels ( Figure 6A-D) . To test if AR required activation to increase gene transcription, transfected female cells were treated with DHT, however, no further induction was observed. HSL mRNA increased modestly upon DHT treatment but was not statistically significant ( Figure 6D ). In contrast, DHT treatment of non-transfected, male MDMs significantly induced transcription of all four genes ( Figure  6 ), consistent with earlier studies (9) .
Discussion
This study demonstrates that AR, activated or unactivated, can act as a molecular switch in human vascular endothelial cells to activate NF-kB thereby driving sex-specific NF-kBdependent VCAM-1 expression and monocyte adhesion, key early steps in atherosclerosis establishment. Conversely, this study has revealed that AR alone, unactivated or activated, is not sufficient for regulating the sex-specific expression of ICAM-1 in ECs or genes involved in lipid metabolism in female-derived MDMs. Increasing AR levels in MDMs from female donors did not significantly increase ACAT, LAL, HSL or CAV-2 expression, even after DHT activation, suggesting the AR could be interacting with other cofactors or nuclear factors in male cells to increase lipid metabolism genes and subsequent lipid accumulation, factors that could be missing or poorly expressed in female versus male cells.
The most striking finding of this study is that AR is acting as a molecular switch enabling or disabling proinflammatory effects in human ECs via its activation of NF-kB. It has previously been shown by our laboratory that DHT dosedependently mediates upregulation of VCAM-1 and monocyte-endothelial cell adhesion in male cells through the AR, as the effect of DHT could be significantly abrogated by pharmacological blockade with an AR antagonist (8) . Accordingly, this effect was postulated to be sex-specific owing to the higher levels of AR in male compared to female ECs (7) . We have now shown conclusively that in male ECs VCAM-1 expression is dependent upon AR and demonstrate that by simply increasing AR in female endothelial cells, their behavior changes to mimic male cells. Male-specific expression of AR activates NF-kB and subsequently VCAM-1 expression in male endothelial cells, leading to increased monocyte adhesion (7) . Female cells that inherently express less AR are therefore protected from this early atherosclerotic inflammatory event. These results exclusively demonstrate the pivotal role AR plays in this androgen-induced proinflammatory, proatherogenic process. The role of AR in such proinflammatory activities and the gender-specific expression of AR could be responsible, at least in part, for the male predisposition to early onset atherosclerosis.
The finding that AR was central to the sex-specific expression of VCAM-1, but not ICAM-1, is most likely related to the key dependence of VCAM-1 expression on NF-kB (7, 11) . Previous promoter-deletion studies have demonstrated the significance of the NF-kB binding site in androgeninduced VCAM-1 expression (7) and that 4-400 nmol/L DHT-stimulated AR activates NF-kB and that it is active NF-kB that drives DHT-induced VCAM-1 expression in male ECs. The failure of AR to induce ICAM-1 expression in female-derived cells appears not to be due to a lack of induction of NF-kB, as we demonstrated that AR can also drive NF-kB activity in phenotypically female cells. Instead, such findings could be a consequence of sex-specific expression of other nuclear factors, as ICAM-1 is regulated by multiple transcription factors acting in concert (17) , or a consequence of sex differences in the expression of specific nuclear cofactors. There is evidence for promoter-specific regulation of several NF-kB-dependent genes, including ICAM-1 and VCAM-1, coordinated by an array of NF-kB cofactors. For example, poly (ADP-ribose) polymerase-1 (PARP-1) is essential for NF-kB dependent ICAM-1, but not VCAM-1, expression in murine smooth muscle cells (18) . Similarly, coactivator-associated arginine methyltransferase-1 (CARM-1) exhibits promoter-specific regulation of several NF-kB dependent genes, including ICAM-1, in CARM-1 knockout cells (19) . There is no evidence to date for sexspecific expression of PARP-1 or CARM-1, however, we have observed lower expression of another cofactor, p300, in immunostained sections of mesenteric arteries from female compared to male subjects (unpublished observations). p300 directly associates with PARP-1 and both p50 and p65 (RelA) subunits of NF-kB to synergistically activate transcription (20) . Acetylation of PARP-1 by p300/CBP is also necessary for coactivation of NF-kB transcription (21) . Further investigation is warranted into possible gender differences in the expression of these or a growing number of cofactors that interact with the AR and/or NF-kB (19, 22) and any subsequent contribution to sex-specific inflammatory signaling.
Limiting levels of other nuclear factors could also explain the lack of induction of lipoprotein metabolism genes in female MDMs in the presence of increased levels of AR and DHT. This and previous studies show that these same genes are readily inducible by pharmacological and physiological concentrations of DHT in male cells, and inhibition by ARspecific antagonists demonstrates AR dependence (9) . AR is therefore important for male regulation of the lipid metabolism genes, however, as female cells with increased AR remain unresponsive to DHT in this regard, it suggests that AR must be acting with other cofactors/nuclear factors and itself is not sufficient to drive expression of lipid metabolism genes. Like ICAM-1, transcriptional control of the lipid metabolism genes is highly complex and involves concerted combinations of transcription factors. There is evidence for an NF-kB role in LAL and HSL transcriptional control but no obvious involvement in CAV-2 or ACAT1 expression (23, 24) . The androgen-sensitivity of HSL and CAV-2 in male MDMs could instead be a consequence of their regulation by the sterol regulatory element binding protein (SREBP) (23) , whose activity is AR-dependent via upstream regulation of escort proteins, SCAP (SREBP cleavage activating protein) and insig-1 and -2 (25) .
In summary, the data presented here show that AR acts as a molecular switch that promotes early proatherogenic processes in male ECs via NF-kB activation. Increasing AR expression in female ECs increased VCAM-1 expression and monocyte-endothelial cell adhesion, unequivocally demonstrating the AR-dependence of these key early steps in early lesion development. Low expression of AR in female ECs limits VCAM-1 activation in response to androgens and could contribute to the gender bias in cardiovascular disease. Inability of AR overexpression in phenotypically female cells to induce other atherogenic genes suggests sex-specific expression of other transcription factors or cofactors that act with AR or NF-kB could also play a role in limiting vascular inflammation and early lesion development in women and deserve further study.
